A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).

@article{Wolf2007APM,
  title={A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).},
  author={Juergen Wolf and Firmin Janssen and Henrik Lublin and Raimo K R Salokangas and Herv{\'e} Allain and Enrico Smeraldi and Miquel Bernardo and Helen Millar and Miranda Pans and Christine Adelbrecht and Jim Laughton and Christian Werner and Wolfgang Maier},
  journal={Current medical research and opinion},
  year={2007},
  volume={23 10},
  pages={2313-23}
}
OBJECTIVE To examine the effectiveness of aripiprazole in schizophrenia in a naturalistic setting in 14 European countries. METHODS This multicentre, open-label study of aripiprazole evaluated outpatients with schizophrenia for whom a medication switch was clinically reasonable or antipsychotic initiation was required. Patients (n = 833) were randomized in a 4:1 ratio to aripiprazole (recommended starting dose 15 mg/day, permitted adjustment 10-30 mg/day) (n = 680) or another antipsychotic… CONTINUE READING